Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First-Line Docetaxel: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (SAKK 08/11)Richard Cathomas, Silke Gillessen, Christian Rothermundt et al.|The Prostate|2016Cited by 20
2500 Orteronel (Ort) maintenance therapy in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) and non-progressive disease after first-line docetaxel (Doc) therapy: Results of a multicenter randomized double-blind placebo-controlled phase III trial (SAKK 08/11)Richard Cathomas, Silke Gillessen, S. Crabb et al.|European Journal of Cancer|2015Cited by 0